The Efficacy of Postoperative Cyclic Oral Contraceptives after Gonadotropin-Releasing Hormone Agonist Therapy to Prevent Endometrioma Recurrence in Adolescents

被引:11
|
作者
Seo, Jong-Wook [1 ]
Lee, Dong-Yun [1 ]
Yoon, Byung-Koo [1 ]
Choi, DooSeok [1 ]
机构
[1] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Obstet & Gynecol, 81 Irwon Ro, Seoul 06351, South Korea
关键词
Postoperative medical treatment; Endometrioma recurrence; Adolescent; BONE-MINERAL DENSITY; YOUNG FERTILE WOMEN; OVARIAN ENDOMETRIOMA; RISK-FACTORS; 2ND SURGERY; TURNOVER; DROSPIRENONE; RESERVE; DISEASE; IMPACT;
D O I
10.1016/j.jpag.2016.10.004
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Study Objective: Young age is a possible risk factor of endometriosis recurrence after surgery. However, the efficacy of postoperative medical treatment has not been well addressed in adolescents. The purpose of this study was to evaluate whether postoperative medical treatment is as effective in adolescents as it is in adults in the prevention of endometrioma recurrence. Design: A retrospective cohort study. Setting: Samsung Medical Center, Seoul, Korea. Participants: This study included 176 reproductive-aged women who underwent conservative laparoscopic surgery for pathologyconfirmed endometrioma. Women were classified into 2 groups according to age: adolescents (20 years of age and younger, n = 34; group I) and reproductive-aged women (aged 25-35 years, n = 142; group II). Interventions: The same surgeon performed all of the surgeries for uniformity. Postoperatively, patients were treated monthly with a gonadotropin-releasing hormone agonist depot for 3-6 months, followed by cyclic oral contraceptives. Main Outcome Measures: Endometrioma recurrence was determined using ultrasonography. The recurrence rate of endometrioma was compared between the 2 groups. Results: During the treatment period (median, 41.0 months; range, 6-159 months), recurrence was noted in 8 cases (4.5%). After adjusting for confounders (which were statistically different between the groups), the cumulative proportion of recurrent endometriomas after 60 months was comparable between the 2 groups (5.3% in group I and 8.5% in group II). Conclusion: Long-term postoperative medical treatment with cyclic oral contraceptives after a gonadotropin-releasing hormone agonist can be as effective in adolescents as it is in adults in the prevention of endometrioma recurrence.
引用
收藏
页码:223 / 227
页数:5
相关论文
共 50 条
  • [1] Postoperative levonorgestrel-releasing intrauterine system versus oral contraceptives after gonadotropin-releasing hormone agonist treatment for preventing endometrioma recurrence
    Cho, Sihyun
    Jung, Ji Ann
    Lee, Yousun
    Kim, Hye Yeon
    Seo, Seok Kyo
    Choi, Young Sik
    Lee, Ji Sung
    Lee, Byung Seok
    [J]. ACTA OBSTETRICIA ET GYNECOLOGICA SCANDINAVICA, 2014, 93 (01) : 38 - 44
  • [2] Efficacy of Post-Operative Medication to Prevent Recurrence of Endometrioma: Cyclic Oral Contraceptive (OC) After Gonadotropin-Releasing Hormone (GnRH) Agonist Versus Dienogest
    Choi, Seung-Hye
    Kim, Sung Eun
    Lim, Hyun Hye
    Lee, Dong-Yun
    Choi, DooSeok
    [J]. JOURNAL OF KOREAN MEDICAL SCIENCE, 2022, 37 (26)
  • [3] Postoperative Long-term Maintenance Therapy with Oral Contraceptives, after Gonadotropin-releasing Hormone Analog Treatment in Women with Ovarian Endometrioma
    Park, Hyun-Jung
    Koo, Young-Ah
    Yoon, Byung-Koo
    Choi, DooSeok
    [J]. JOURNAL OF MINIMALLY INVASIVE GYNECOLOGY, 2009, 16 (01) : 34 - 39
  • [4] Comparison of combined oral contraceptive after gonadotropin-releasing hormone agonist versus dienogest as maintenance therapy to prevent recurrence after surgery of endometriosis
    Baek, Hyewon
    Seo, Jong-Wook
    Choo, Sung Pil
    Inok, Lee
    Han, Sangwon
    Chung, Jae Eun
    [J]. MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY, 2018, 25 (12): : 1514 - 1514
  • [5] Recurrence of uterine adenomyosis after administration of gonadotropin-releasing hormone agonist and the efficacy of dienogest
    Matsushima, Takashi
    Akira, Shigeo
    Yoneyama, Koichi
    Takeshita, Toshiyuki
    [J]. GYNECOLOGICAL ENDOCRINOLOGY, 2020, 36 (06) : 521 - 524
  • [6] Differences between gonadotropin-releasing hormone agonist and oral contraceptives for the treatment of endometriosis
    Aisaka, K
    Doi, M
    Ikezuki, Y
    Obata, S
    [J]. OBSTETRICS AND GYNECOLOGY, 2005, 105 (04): : 63S - 63S
  • [7] Preventive therapeutic options for postoperative recurrence of ovarian endometrioma: gonadotropin-releasing hormone agonist with or without levonorgestrel intrauterine system insertion
    Shi-Yang Zhu
    Yu-Shi Wu
    Zhi-Yue Gu
    Jing Zhang
    Shuang-Zheng Jia
    Jing-Hua Shi
    Yi Dai
    Jin-Hua Leng
    Xiao-Yan Li
    [J]. Archives of Gynecology and Obstetrics, 2021, 303 : 533 - 539
  • [8] Preventive therapeutic options for postoperative recurrence of ovarian endometrioma: gonadotropin-releasing hormone agonist with or without levonorgestrel intrauterine system insertion
    Zhu, Shi-Yang
    Wu, Yu-Shi
    Gu, Zhi-Yue
    Zhang, Jing
    Jia, Shuang-Zheng
    Shi, Jing-Hua
    Dai, Yi
    Leng, Jin-Hua
    Li, Xiao-Yan
    [J]. ARCHIVES OF GYNECOLOGY AND OBSTETRICS, 2021, 303 (02) : 533 - 539
  • [9] Efficacy of preoperative gonadotropin-releasing hormone agonist therapy for laparoscopic myomectomy
    Kotani, Y.
    Shiota, M.
    Umemoto, M.
    Tobiume, T.
    Shimaoka, M.
    Hoshiai, H.
    [J]. ASIAN JOURNAL OF ENDOSCOPIC SURGERY, 2009, 2 (01) : 24 - 28
  • [10] Comparison of long-term use of combined oral contraceptive after gonadotropin-releasing hormone agonist plus add-back therapy versus dienogest to prevent recurrence of ovarian endometrioma after surgery
    Seo, Jong-Wook
    Lee, Dong-Yun
    Kim, Sung Eun
    Yoon, Byung-Koo
    Choi, DooSeok
    [J]. EUROPEAN JOURNAL OF OBSTETRICS & GYNECOLOGY AND REPRODUCTIVE BIOLOGY, 2019, 236 : 53 - 57